Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 4, Pages 884
Publisher
MDPI AG
Online
2020-02-26
DOI
10.3390/molecules25040884
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2018 FDA drug approvals
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- ONECUT2 is a driver of neuroendocrine prostate cancer
- (2019) Haiyang Guo et al. Nature Communications
- Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
- (2019) Lee D Cranmer OncoTargets and Therapy
- Successes, failures, and future prospects of prodrugs and their clinical impact
- (2019) Anas Najjar et al. Expert Opinion on Drug Discovery
- Tardive Dyskinesia: Treatment Update
- (2019) Divya Arya et al. Current Neurology and Neuroscience Reports
- Pretomanid: First Approval
- (2019) Susan J. Keam DRUGS
- Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients
- (2018) Michael A. Lyons ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
- (2018) Sheridan M. Hoy DRUGS
- Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea
- (2018) Katherine A. Lyseng-Williamson DRUGS
- Fostemsavir
- (2018) Pedro Cahn et al. Current Opinion in HIV and AIDS
- Sigma Receptors as Endoplasmic Reticulum Stress “Gatekeepers” and their Modulators as Emerging New Weapons in the Fight Against Cancer
- (2018) Anna Tesei et al. Frontiers in Pharmacology
- Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects
- (2018) Pierre-Eric Juif et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The prodrug approach in the era of drug design
- (2018) Anas Najjar et al. Expert Opinion on Drug Delivery
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect
- (2018) Cho Rong Hong et al. NEOPLASIA
- The discovery and development of romidepsin for the treatment of T-cell lymphoma
- (2017) Piotr Smolewski et al. Expert Opinion on Drug Discovery
- 2016 FDA drug approvals
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
- (2017) Graciana L. Galiana et al. Drugs in research & development
- Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review
- (2017) Maguy Saffouh El Hajj et al. International Journal of Clinical Pharmacy
- Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
- (2017) Reese A. Cosimi et al. Open Forum Infectious Diseases
- Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity
- (2016) Wen Wee Ma et al. CANCER
- The role of tenofovir alafenamide in future HIV management
- (2016) A Antela et al. HIV MEDICINE
- 2015 FDA drug approvals
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
- (2016) Yehenew Asemamaw Ebstie et al. Drug Design Development and Therapy
- Sacubitril/Valsartan (Entresto) for Heart Failure
- (2015) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel
- (2015) Eva Caroff et al. JOURNAL OF MEDICINAL CHEMISTRY
- BMS-663068, a safe and effective HIV-1 attachment inhibitor
- (2015) Ester Ballana et al. Lancet HIV
- Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
- (2015) Jacob P Lalezari et al. Lancet HIV
- Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Efficacy Summary
- (2013) W. O'Riordan et al. CLINICAL INFECTIOUS DISEASES
- Eslicarbazepine acetate: An update on efficacy and safety in epilepsy
- (2013) Alberto Verrotti et al. EPILEPSY RESEARCH
- Aripiprazole
- (2012) Jamie D. Croxtall CNS DRUGS
- Aripiprazole
- (2011) Sohita Dhillon DRUGS
- The role of proximity orientation in intramolecular proton transfer reactions
- (2011) Rafik Karaman Computational and Theoretical Chemistry
- Pharmacokinetic evaluation of fosaprepitant dimeglumine
- (2010) Francheska Colon-Gonzalez et al. Expert Opinion on Drug Metabolism & Toxicology
- Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
- (2010) Eisuke Murakami et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative
- (2010) Vanessa Villard et al. JOURNAL OF PSYCHOPHARMACOLOGY
- An Oxyferrous Heme/Protein-based Radical Intermediate Is Catalytically Competent in the Catalase Reaction ofMycobacterium tuberculosisCatalase-Peroxidase (KatG)
- (2009) Javier Suarez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Primaquine revisited six decades after its discovery
- (2008) Nuno Vale et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started